ImmunoGen, Inc. (NASDAQ:IMGN)

CAPS Rating: 4 out of 5

The Company develops antibody-based anticancer therapeutics.

Recs

0
Player Avatar Safetymatt (< 20) Submitted: 4/23/2013 12:24:28 AM : Outperform Start Price: $14.74 IMGN Score: -33.52

Been watching for a while and like the potential possibilities. Gambling on IMGN

Featured Broker Partners


Advertisement